Targeted therapy for breast cancer may be medication or injection, related to the type of drug, for example, pyrrolitinib, a targeted drug for anti-HER-2 therapy, is given orally, while trastuzumab, another targeted drug for anti-HER-2 therapy, is given by infusion.
1. Piratinib: it is a target drug for anti-HER-2 therapy, often used in combination with capecitabine for HER-2 positive, previously unused or recurrent or metastatic breast cancer after using trastuzumab. It is given orally at the recommended dosage, and may have side effects such as nausea and lowering of white blood cells, and is contraindicated in people who are allergic to it, and the HER-2 status needs to be detected prior to its use.
2. Trastuzumab: it is an anti-HER-2 therapeutic targeting drug, applicable to postoperative adjuvant treatment of HER-2 positive breast cancer, also applicable to first-line treatment or palliative treatment of HER-2 positive metastatic breast cancer, administered by intravenous infusion according to the recommended dosage, there may be side effects such as fatigue, chest pain, rash, etc., and it is forbidden to use for those who are allergic to it, and it is necessary to monitor the cardiac side effects during the period of use of the drug.
So breast cancer targeted drugs may be taking drugs or injections, and the type of drug related, it is recommended that the patient under the guidance of the doctor to choose the right targeted drugs for themselves.